JP2020512344A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512344A5 JP2020512344A5 JP2019552991A JP2019552991A JP2020512344A5 JP 2020512344 A5 JP2020512344 A5 JP 2020512344A5 JP 2019552991 A JP2019552991 A JP 2019552991A JP 2019552991 A JP2019552991 A JP 2019552991A JP 2020512344 A5 JP2020512344 A5 JP 2020512344A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762476940P | 2017-03-27 | 2017-03-27 | |
| US62/476,940 | 2017-03-27 | ||
| PCT/US2018/024296 WO2018183173A1 (en) | 2017-03-27 | 2018-03-26 | Anti il-36r antibodies combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020512344A JP2020512344A (ja) | 2020-04-23 |
| JP2020512344A5 true JP2020512344A5 (enExample) | 2021-04-30 |
Family
ID=62002399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019552991A Pending JP2020512344A (ja) | 2017-03-27 | 2018-03-26 | 抗ｉｌ−３６ｒ抗体併用治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20180273627A1 (enExample) |
| EP (1) | EP3601350A1 (enExample) |
| JP (1) | JP2020512344A (enExample) |
| CN (1) | CN110461877A (enExample) |
| WO (1) | WO2018183173A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10526410B2 (en) | 2015-04-15 | 2020-01-07 | Anaptysbio, Inc. | Antibodies directed against interleukin 36 receptor (IL-36R) |
| AU2019236105B2 (en) | 2018-03-14 | 2025-07-31 | Boehringer Ingelheim International Gmbh | Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis |
| WO2019177883A2 (en) * | 2018-03-14 | 2019-09-19 | Boehringer Ingelheim International Gmbh | Use of anti-il-36r antibodies for treatment of inflammatory bowel disease |
| KR102895164B1 (ko) | 2018-07-16 | 2025-12-04 | 리제너론 파마슈티칼스 인코포레이티드 | 항-il36r 항체 |
| US11730812B2 (en) | 2019-03-08 | 2023-08-22 | Boehringer Ingelheim International Gmbh | Anti-IL-36R antibody formulations |
| US20230096620A1 (en) * | 2019-04-17 | 2023-03-30 | Millennium Pharmaceuticals, Inc. | Alpha4beta7 inhibitor and il-23 inhibitor combination therapy |
| CN111848780A (zh) * | 2019-04-24 | 2020-10-30 | 华东师范大学 | 一种IL-36的可溶性受体sIL-36R及其应用 |
| AR120913A1 (es) * | 2019-12-27 | 2022-03-30 | Teijin Pharma Ltd | Anticuerpo que inhibe específicamente la señalización de il-36r |
| US20230235040A1 (en) * | 2020-06-22 | 2023-07-27 | Almirall, S.A. | Anti-il-36 antibodies and methods of use thereof |
| MX2023000763A (es) | 2020-07-17 | 2023-02-13 | Boehringer Ingelheim Int | Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas. |
| WO2022026832A1 (en) | 2020-07-30 | 2022-02-03 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for ichthyosis |
| WO2022026829A1 (en) | 2020-07-30 | 2022-02-03 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity |
| CN112094349B (zh) * | 2020-11-04 | 2021-02-09 | 上海华奥泰生物药业股份有限公司 | 靶向于白介素36r的抗体及其制备方法和应用 |
| WO2022150642A1 (en) | 2021-01-08 | 2022-07-14 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa |
| WO2022150644A1 (en) | 2021-01-08 | 2022-07-14 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for acne |
| CN114907477A (zh) * | 2021-02-08 | 2022-08-16 | 上海普铭生物科技有限公司 | 抗人il-36r抗体及其应用 |
| BR112023014103A2 (pt) * | 2021-03-04 | 2023-10-10 | Boehringer Ingelheim Int | Métodos para o tratamento de gpp |
| EP4305207A2 (en) | 2021-03-12 | 2024-01-17 | Boehringer Ingelheim International GmbH | Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis |
| WO2022262828A1 (zh) * | 2021-06-18 | 2022-12-22 | 正大天晴药业集团股份有限公司 | 抗il-36r抗体及其用途 |
| TW202323293A (zh) * | 2021-10-29 | 2023-06-16 | 新加坡商創響私人有限公司 | 新型抗ｉｌ－３６ｒ抗體 |
| CN115724975B (zh) | 2022-10-20 | 2026-06-09 | 江苏荃信生物医药股份有限公司 | 抗人白介素36受体单克隆抗体及其应用 |
| CN117357474B (zh) * | 2022-12-19 | 2024-12-03 | 江苏荃信生物医药股份有限公司 | 抗人白介素36受体单克隆抗体及液体制剂 |
| WO2024175031A1 (zh) * | 2023-02-21 | 2024-08-29 | 江苏恒瑞医药股份有限公司 | Il-36r结合蛋白及其医药用途 |
| WO2024251927A2 (en) * | 2023-06-09 | 2024-12-12 | Boehringer Ingelheim International Gmbh | Methods for the treatment and prevention of gpp |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| WO1990003430A1 (en) | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| CA2140933A1 (en) | 1992-08-21 | 1994-02-22 | Paula M. Jardieu | Method for treating an lfa-1 mediated disorder |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| SI2780373T1 (sl) * | 2011-11-16 | 2019-12-31 | Boehringer Ingelheim International Gmbh | Protitelesa proti IL-36R |
| US10526410B2 (en) * | 2015-04-15 | 2020-01-07 | Anaptysbio, Inc. | Antibodies directed against interleukin 36 receptor (IL-36R) |
-
2018
- 2018-03-26 EP EP18718268.8A patent/EP3601350A1/en not_active Withdrawn
- 2018-03-26 WO PCT/US2018/024296 patent/WO2018183173A1/en not_active Ceased
- 2018-03-26 CN CN201880022517.7A patent/CN110461877A/zh active Pending
- 2018-03-26 JP JP2019552991A patent/JP2020512344A/ja active Pending
- 2018-03-26 US US15/935,519 patent/US20180273627A1/en not_active Abandoned
-
2022
- 2022-09-07 US US17/930,072 patent/US20230044739A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9475872B2 (en) | Nucleic acid molecules encoding moonoclonal antibodies speceific for IL17F | |
| JP2021531254A5 (enExample) | ||
| US12441785B2 (en) | Methods of treating inflammatory diseases | |
| US20250304674A1 (en) | Methods of treating inflammatory diseases | |
| US10875916B2 (en) | Nucleic acid molecules encoding monoclonal antibodies specific for IL-17F | |
| US20180142010A1 (en) | Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant | |
| JP2021526534A5 (enExample) | ||
| JP2016524592A5 (enExample) | ||
| JP2017506626A5 (enExample) | ||
| JP2020502996A5 (enExample) | ||
| RU2015112024A (ru) | Способы диагностики и лечения воспалительного заболевания кишечника | |
| CN106170496B (zh) | 针对纤连蛋白-eda的免疫球蛋白样分子 | |
| RU2018118177A (ru) | Способы лечения нерентгенографического аксиального спондилоартрита, используя антагонисты интерлейкина-17 (il-17) | |
| RU2018129874A (ru) | Антитела против фактора свертывания xi | |
| US20200299378A1 (en) | Methods of treating diseases | |
| JPWO2020059847A5 (enExample) | ||
| JP2018529661A5 (enExample) | ||
| JP2022531556A5 (enExample) | ||
| JP2019528285A5 (enExample) | ||
| Mounach et al. | Stevens-Johnson syndrome complicating adalimumab therapy in rheumatoid arthritis disease | |
| JP2019528306A5 (enExample) | ||
| JP2019517508A5 (enExample) | ||
| JP2020503013A5 (enExample) | ||
| JP2017524359A5 (enExample) | ||
| JP2013539354A5 (enExample) |